CTLA4 and melanoma: A retrospective analysis of 133 tumor samples from patients with metastatic non-small cell lung cancer, melanoma, or renal cell cancer after receiving radiotherapy with or without combined immunotherapy showed that the combination of focal palliative radiation and CTLA-4 and/or PD-1 inhibitors was well tolerated.